Keith D. Eaton

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Julie R. Brahmer, Scott S. Tykodi, Laura Q.M. Chow et al. · New England Journal of Medicine · 2012 · 8K citations · Full text

Life Sciences, Immunology, Oncology +17

Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung Cancer

Lecia V. Sequist, Benjamin Besse, Thomas J. Lynch et al. · Journal of Clinical Oncology · 2010 · 426 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase II Study of Daily Sunitinib in FDG-PET–Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation

Laurie L. Carr, David A. Mankoff, Bernardo Goulart et al. · Clinical Cancer Research · 2010 · 418 citations · Full text

Medicine, Oncology, Pharmacology +17

Plasma Processing Conditions Substantially Influence Circulating microRNA Biomarker Levels

Heather H. Cheng, Hye Son Yi, Yeon-Ju Kim et al. · PLoS ONE · 2013 · 309 citations · Full text

Life Sciences, Biomedical Sciences, Molecular Biology +16

Validation and Implementation of Targeted Capture and Sequencing for the Detection of Actionable Mutation, Copy Number Variation, and Gene Rearrangement in Clinical Cancer Specimens

Colin C. Pritchard, Stephen J. Salipante, Karen M. Koehler et al. · Journal of Molecular Diagnostics · 2013 · 279 citations · Full text

Medicine, Molecular Biology, Oncology +16